share_log

Pfizer | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

Pfizer | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

辉瑞 | 11-K:员工持股年度报告
美股sec公告 ·  06/11 14:43
Moomoo AI 已提取核心信息
Pfizer Inc. has filed its annual report on Form 11-K with the SEC for the fiscal year ended December 31, 2023. The report includes audited financial statements of the Pfizer Savings Plan, which is available to employees for stock purchase, savings, and similar plans. The independent audit, conducted by KPMG LLP, concluded that the financial statements present fairly the net assets available for plan benefits as of December 31, 2023, and the changes in net assets for the year in accordance with U.S. GAAP. The report details the Plan's investments, including Pfizer Inc. common stock, mutual funds, and other assets totaling approximately $19.7 billion, an increase from the previous year's $18 billion. The Plan experienced a net investment gain of over $2 billion for...Show More
Pfizer Inc. has filed its annual report on Form 11-K with the SEC for the fiscal year ended December 31, 2023. The report includes audited financial statements of the Pfizer Savings Plan, which is available to employees for stock purchase, savings, and similar plans. The independent audit, conducted by KPMG LLP, concluded that the financial statements present fairly the net assets available for plan benefits as of December 31, 2023, and the changes in net assets for the year in accordance with U.S. GAAP. The report details the Plan's investments, including Pfizer Inc. common stock, mutual funds, and other assets totaling approximately $19.7 billion, an increase from the previous year's $18 billion. The Plan experienced a net investment gain of over $2 billion for the year. The report also outlines the Plan's administrative details, contributions, rollovers, and participant-directed investments. Notably, the Plan underwent several mergers and transfers due to Pfizer's acquisitions, including Trillium Therapeutics, Arena Pharmaceuticals, ReViral Ltd., and Global Blood Therapeutics. The Plan is subject to ERISA and the Internal Revenue Code, with no current audits in progress for tax periods. The report also mentions subsequent events, including the acquisition of Seagen Inc. and the transfer of its 401(k) plan into the Pfizer Savings Plan.
辉瑞公司已向SEC提交了截至2023年12月31日的财政年度的Form 11-K的年报。该报告包括辉瑞储蓄计划的审计财务报表,该计划可供员工购买股票,储蓄和类似计划。KPMG LLP进行的独立审计结论是,根据美国通用会计准则,财务报表公正地呈现了2023年12月31日可用于计划福利的净资产以及该年度净资产的变化。该报告详细说明了该计划的投资情况,包括辉瑞公司普通股、所有基金类型和其他资产,总计约197亿美元,较上一年的180亿美元有所增加。该计划在该年度获得超过20亿美元的净投资收益。该报告还概述了该计划的行政细节,捐款,滚存和参与者指定的投资。值得注意的是,由于辉瑞公司的收购,包括Trill...展开全部
辉瑞公司已向SEC提交了截至2023年12月31日的财政年度的Form 11-K的年报。该报告包括辉瑞储蓄计划的审计财务报表,该计划可供员工购买股票,储蓄和类似计划。KPMG LLP进行的独立审计结论是,根据美国通用会计准则,财务报表公正地呈现了2023年12月31日可用于计划福利的净资产以及该年度净资产的变化。该报告详细说明了该计划的投资情况,包括辉瑞公司普通股、所有基金类型和其他资产,总计约197亿美元,较上一年的180亿美元有所增加。该计划在该年度获得超过20亿美元的净投资收益。该报告还概述了该计划的行政细节,捐款,滚存和参与者指定的投资。值得注意的是,由于辉瑞公司的收购,包括Trillium Therapeutics,Arena Pharmaceuticals,ReViral Ltd.和全球血液疗法等公司,该计划经历了几次合并和转让。该计划适用于ERISA和内部税收法规,目前没有为税务期间进行的审计。报告还提到了后续事件,包括Seagen Inc.的收购以及其401(k)计划转入辉瑞储蓄计划。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息